Dual biological therapy and small molecules in pediatric inflammatory bowel disease
Pharmacological Research · 2023
DOI: 10.1016/j.phrs.2023.106935 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacological Research, 2023. Verfasst von Francesca Penagini und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, "Vittore Buzzi" Children's Hospital, Milano, Italy. Electronic address: Francesca.penagini@asst-fbf-sacco.it. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Gastrointestinal Agents, Biological Therapy, Biological Products. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Inflammatory bowel diseases (IBDs) including Crohn's disease (CD), ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBD-U) are chronic inflammatory disorders which can affect the gastrointestinal tract. Anti-tumor necrosis factors antibodies (anti-TNFα) such as infliximab (IFX) and adalimumab (ADA) are the first line biological therapy for severe or complicated IBDs in pediatric age. Second line therapeutic options as vedolizumab (VDZ) and ustekinumab (UST) are currently used off-label in pediatric age. Furthermore, despite optimization of biologics, a great proportion of patients may fail to respond to biologic agents (up to 30%) or lose response over the time (around 50%) hence these patients may be left without another valid therapeutic option. Consequently, several efforts have been made in the last years in order to develop new drugs and to contrive new therapeutic strategies. Small molecule drugs (SMDs) and combination therapy with either two biologic agents or with a SMD and a biological agent have recently been proposed. Data on safety and efficacy of these new therapeutic options are limited. The objective of the present review is to summarize the most up-to-date available literature in pediatric IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, "Vittore Buzzi" Children's Hospital, Milano, Italy. Electronic address: Francesca.penagini@asst-fbf-sacco.it.
- Department of Pediatrics, "Vittore Buzzi" Children's Hospital, Milano, Italy.
- Department of Pediatrics, "Vittore Buzzi" Children's Hospital, Milano, Italy; Pediatric and Adolescent Unit, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy.
- Department of Pediatrics, "Vittore Buzzi" Children's Hospital, Milano, Italy; Department of Biomedical and Clinical Science "L. Sacco", University of Milano, Milano, Italy.
Zitieren
APA
Penagini, F., Lonoce, L., Abbattista, L., Silvera, V., Rendo, G., Cococcioni, L., Dilillo, D., Calcaterra, V., & Zuccotti, G. V. (2023). Dual biological therapy and small molecules in pediatric inflammatory bowel disease. Pharmacological Research. https://doi.org/10.1016/j.phrs.2023.106935
Vancouver
Penagini F, Lonoce L, Abbattista L, Silvera V, Rendo G, Cococcioni L, et al. Dual biological therapy and small molecules in pediatric inflammatory bowel disease. Pharmacological Research. 2023. doi:10.1016/j.phrs.2023.106935
BibTeX
@article{Penagini2023,
author = {Penagini, Francesca and Lonoce, Luisa and Abbattista, Luisa and Silvera, Valentina and Rendo, Giulia and Cococcioni, Lucia and Dilillo, Dario and Calcaterra, Valeria and Zuccotti, Gian Vincenzo},
title = {Dual biological therapy and small molecules in pediatric inflammatory bowel disease},
journal = {Pharmacological Research},
year = {2023},
doi = {10.1016/j.phrs.2023.106935}
}
EUVIMED